HEPA Archives - BioTuesdays

Developments

Former Hepion CEO sues over departure; cites bad faith dealings with investor

Former Hepion Pharmaceuticals (NASDAQ:HEPA) CEO, Robert Foster, PharmD, PhD, is suing the company and its Board members for illegal termination of his employment, breach of contract, and breach of the covenant of good...

June 13, 2024

Developments Markets

Hepion reports restructuring and resignations; Brookline downgrades to hold and suspends target

Hepion Pharmaceuticals (NASDAQ:HEPA) announced a restructuring that, among other things, will suspend the enrollment of new patients in the Phase 2b ‘ASCEND-NASH’ clinical trial of its lead drug candidate, rencofilstat...

December 7, 2023

Developments

Hepion’s rencofilstat demonstrates significant reduction in liver stiffness in patients with advanced MASH liver disease

Hepion Pharmaceuticals (NASDAQ:HEPA) presented new data from its Phase 2 ALTITUDE-NASH trial demonstrating that 17 weeks of rencofilstat treatment significantly reduced liver stiffness in subjects with advanced F3...

November 13, 2023

Developments

Hepion’s rencofilstat demonstrates anti-cancer activity in hepatitis C-associated cancer model

Hepion Pharmaceuticals (NASDAQ:HEPA) published a new research study in mice where rencofilstat prevented the growth of human hepatitis C virus (“HCV”)-associated liver tumors. HCV-infected mice developed small liver...

October 25, 2023

Developments

Hepion in $5-million registered direct offering

Hepion Pharmaceuticals (NASDAQ:HEPA) entered into a securities purchase agreement with a healthcare-focused institutional investor for the purchase of 980,393 shares of the company at a purchase price of $5.10 per share...

September 29, 2023

Developments

Hepion discovers novel rencofilstat action in liver cancer

Hepion Pharmaceuticals (NASDAQ:HEPA) reported new research findings that discovered a mechanism by which the company’s lead drug candidate, rencofilstat, may exert anti-cancer activity. The research examined...

September 20, 2023

Developments

Hepion’s rencofilstat shows positive outcomes in idiopathic pulmonary fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of rencofilstat on lung tissue obtained from patients with idiopathic pulmonary fibrosis (IPF)...

September 14, 2023

Developments

Hepion to present 2 posters at EASL International Liver Congress

Hepion Pharmaceuticals (NASDAQ:HEPA) will present two abstracts for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 taking place June 21 – 24 in...

June 16, 2023

Developments

Hepion Phase 2b ASCEND-NASH trial passes key safety milestone

A data and safety monitoring board (DSMB) has reviewed the current data for Hepion Pharmaceuticals’ (NASDAQ:HEPA) ASCEND-NASH Phase 2b trial with rencofilstat and issued a “study may proceed without modification”...

June 15, 2023

Developments

Hepion to highlight AI-POWR at medical conference

Hepion Pharmaceuticals (NASDAQ:HEPA) will outline the integration of its artificial intelligence and machine learning platform, AI-POWR, into all aspects of its clinical pharmacological programs at the 2023 Canadian...

May 25, 2023

Tag - HEPA

Former Hepion CEO sues over departure; cites bad faith dealings with investor

Hepion reports restructuring and resignations; Brookline downgrades to hold and suspends target

Hepion’s rencofilstat demonstrates significant reduction in liver stiffness in patients with advanced MASH liver disease

Hepion’s rencofilstat demonstrates anti-cancer activity in hepatitis C-associated cancer model

Hepion in $5-million registered direct offering

Hepion discovers novel rencofilstat action in liver cancer

Hepion’s rencofilstat shows positive outcomes in idiopathic pulmonary fibrosis

Hepion to present 2 posters at EASL International Liver Congress

Hepion Phase 2b ASCEND-NASH trial passes key safety milestone

Hepion to highlight AI-POWR at medical conference

General

More